| Venue | Keynote / Special Seminar Room, East Hall 6 | Conference Room, East Hall 5 | Seminar Room E, East Hall 5 | Seminar Room F, East Hall 5 |
|---|---|---|---|---|
| Theme | ||||
| 9:15 | ||||
| 9:30 | Opening ceremony | |||
| 9:45 |
[K-1] New Drug Approval Review: Today and the Future |
|||
| 10:00 | ||||
| 10:15 | ||||
| 10:30 |
[E-1] The latest trends of Antibody purification platform |
|||
| 10:45 | ||||
| 11:00 |
[H-1] China Pharmaceutical Industry -it's growth and future- "Global Market to Global R&D Center" |
[F-1] Development of efficient organic synthetic methods using heterogeneous platinum group catalyst and its application to process chemistry |
||
| 11:15 | ||||
| 11:30 |
[K-2] Complexity of pharmaceutical market and Global Category Leader (GCL) |
[E-2] Characterization of Biopharmaceutical by electric fourier transform mass spectrometer Orbitrap. |
||
| 11:45 | ||||
| 12:00 | ||||
| 12:15 | ||||
| 12:30 | ||||
| 12:45 | ||||
| 13:00 |
[K-3] Drug development and measures carried out at the Japan Pharmaceutical Manufacturers Association |
[H-2] An Introduction to Indonesia's Pharma Market with reference to pharmaceutical legislation, drug price system, insurance system, and drug distribution system |
[E-3] Introduction of Bio-drug Development Supporting Service Leveraging Original Peptide/Protein Producing Technologies. |
[F-2] Asymmetric Synthesis Achieved by Using Sugar Derivatives |
| 13:15 | ||||
| 13:30 | ||||
| 13:45 | ||||
| 14:00 |
[E-4] "Superior analytical solutions for the characterization of biotherapeutics" |
[F-3] Leading edge technology from UK |
||
| 14:15 | ||||
| 14:30 |
[K-4] Quality Assurance of supply chain from procurement of raw materials to distribution of products |
|||
| 14:45 | ||||
| 15:00 |
[H-3] TBA |
|||
| 15:15 |
[E-5] Capillary electrophoresis (CE) involving high sensitive CE-MS and other analytical technologies, accelerate the development of monoclonal antibodies for clinical use |
|||
| 15:30 | ||||
| 15:45 |
[K-5] The Current Status and Issues of Biologics |
|||
| 16:00 | ||||
| 16:15 | ||||
| 16:30 | ||||
| 16:45 | ||||
| 17:00 |
| Venue | Keynote / Special Seminar Room, East Hall 6 | Conference Room, East Hall 5 | Seminar Room E, East Hall 5 | Seminar Room F, East Hall 5 |
|---|---|---|---|---|
| Theme | ||||
| 9:15 | ||||
| 9:30 |
[K-6] The Pharmaceutical Industry's Growth Strategy |
|||
| 9:45 | ||||
| 10:00 | ||||
| 10:15 | ||||
| 10:30 |
[H-5] A Practical Guideline to the Revised Pharmaceutical Affairs Law: A special workshop for English speaking exhibitors & visitors Answers to all your questions about Japan's Pharmaceutical Affairs Law |
[E-6] Contract Manufacturing Service for Biopharmaceuticals |
||
| 10:45 | ||||
| 11:00 | ||||
| 11:15 |
[K-7] Towards A Healthy Society ~Pharmaceutical Industry Will Change Japan~ (Tentative) |
|||
| 11:30 |
[E-7] Implementation of a Single Use Manufacturing Platform for Operational Flexibility and Capacity Expansion |
|||
| 11:45 | ||||
| 12:00 | ||||
| 12:15 | ||||
| 12:30 | ||||
| 12:45 | ||||
| 13:00 |
[K-8] Overview of global regulatory requirements for starting materials (APIs, Excipients, Process Materials, Analytical Reagents) used in pharmaceutical & biopharmaceutical manufacturing processes. |
[H-6] Quality Control in Pharmaceutical Ingredient Manufacturing and Overseas Trends Surrounding Japan |
[E-8] The Future of Outsourcing: The CMO Perspective |
|
| 13:15 | ||||
| 13:30 | ||||
| 13:45 | ||||
| 14:00 | ||||
| 14:15 |
[E-9] Catalent's GPEX Technology: cDNA to Stable-High Expressing Mammalian Cell Line in 4 Months and a 2-5 g/L Production in 6 Months |
|||
| 14:30 | ||||
| 14:45 | ||||
| 15:00 |
[K-9] European vaccine business and Japan Closing - Closing the Vaccine Gap - |
[H-7] A simple explanation of Compliance with the guidelines for management code of the computerized system. |
||
| 15:15 | ||||
| 15:30 |
[E-10] Practical approach to protein expression by GPEx™ technology of Catalent Pharma Solutions |
|||
| 15:45 | ||||
| 16:00 | ||||
| 16:15 | ||||
| 16:30 | ||||
| 16:45 | ||||
| 17:00 |
| Venue | Keynote / Special Seminar Room, East Hall 6 | Conference Room, East Hall 5 | Seminar Room E, East Hall 5 | Seminar Room F, East Hall 5 |
|---|---|---|---|---|
| Theme | ||||
| 9:15 | ||||
| 9:30 |
[K-10] Market outlook of long listed products and generics in Japan |
|||
| 9:45 | ||||
| 10:00 | ||||
| 10:15 | ||||
| 10:30 |
[H-9] Development of peptide-based cancer vaccine |
[E-11] Using Biocatalysis at Commercial Scale |
[F-9] Development of environmentally benign organic transformation reactions catalyzed by hypervalent iodine catalysts |
|
| 10:45 | ||||
| 11:00 |
[K-11] Changing Landscape - From supplier to partner |
|||
| 11:15 | ||||
| 11:30 |
[H-10] Advanced application of iodine |
|||
| 11:45 | ||||
| 12:00 | ||||
| 12:15 | ||||
| 12:30 | ||||
| 12:45 |
[E-12] "FluBlok®" - advantage of a single propriety insect cell line to make all products |
|||
| 13:00 |
[K-12] Some measures in FY 2012 Revision of Medical Fee for generic drug use promotion |
[H-11] Topics and Issues in a Scale-up of the Manufacture of Drug Substances and Intermediates |
[F-10] Solkane® 365mfc: An Environmentally Benign Organic Solvent for Organic Synthesis |
|
| 13:15 | ||||
| 13:30 | ||||
| 13:45 | ||||
| 14:00 |
[H-12] Global Trend of Chemicals Management Regulation - Korea REACH as an Example - |
[E-13] The Strategies for production of Monoclonal Antibody. -Optimization of the purification process for highly efficiency- |
[F-11] Process Chemistry for Unnatural Amino Acids |
|
| 14:15 | ||||
| 14:30 | ||||
| 14:45 | ||||
| 15:00 |
[K-13] Revision of Medical Treatment Fee of Generic Drug |
[H-13] Challenge and perspective of RTRt with PAT analyzers |
[E-14] Development of Upstream and Downstream Manufacturing Process for Vaccines |
[F-12] Development of material production process using high-pressure and high-temperature microreactor |
| 15:15 | ||||
| 15:30 | ||||
| 15:45 | ||||
| 16:00 | ||||
| 16:15 | ||||
| 16:30 | ||||
| 16:45 | ||||
| 17:00 |